Test of blood thinners comparing rivaroxaban vs apixaban
Treatments studied
Part of Heart & circulation clinical trials.
This trial compares the bleeding risk of two commonly used blood thinners—rivaroxaban and apixaban—in people with atrial fibrillation (AF). If you’re starting an anticoagulant for a new AF diagnosis, this may help doctors choose the safer option for you and others.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You were newly diagnosed with atrial fibrillation (AF), confirmed on an ECG.
- A clinician has recommended you start a blood thinner for AF.
- Your kidney function test (creatinine clearance) is more than 15 mL/min.
- You do not have any reasons you cannot take apixaban or rivaroxaban, such as active bleeding or a mechanical heart valve.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two blood thinners, apixaban and rivaroxaban, to see which is safer and works better for veterans with atrial fibrillation (irregular heartbeat). If you're already taking one of these, the study will assign you to one of them.
This trial tests two doses of rivaroxaban (15mg and 20mg) to see how well they prevent strokes in people with non-valvular atrial fibrillation, a type of irregular heartbeat not caused by a heart valve problem. It may be an option if you need blood thinners to lower your stroke risk.
This study tests if apixaban (a newer blood thinner) is safer and works as well as warfarin (a standard blood thinner) for patients on peritoneal dialysis who have atrial fibrillation (an irregular heartbeat). It aims to reduce the risk of stroke and bleeding.
This study compares two blood thinners, edoxaban and apixaban, to see how they affect new brain lesions seen on MRI in people who have had a stroke and also have atrial fibrillation. It aims to find which might be safer for preventing future brain damage.
This trial tests apixaban (a blood thinner) to prevent stroke in people with atrial fibrillation or atrial flutter who have very poor kidney function or are on dialysis. If you qualify, you may help researchers find a safer way to lower stroke risk for this higher-risk group.
This trial tests whether a lower dose of the blood thinner rivaroxaban works as well as the standard dose for people 70 and older with atrial fibrillation (an irregular heartbeat). The goal is to find the safest dose to prevent strokes while reducing bleeding risks.
Hear when a new Atrial fibrillation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.